Novo Nordisk is predicting a 13% drop in sales in 2026. As the company’s patents on Ozempic expire, could cheaper, generic versions give the company a run for its money? Big Take host David Gura talks to Bloomberg reporters Naomi Kresge and Amber Tong about what comes next. (Source: Bloomberg)
www.bloomberg.com
#Generic #Ozempic #Upend #Global #WeightLoss #Drug #Market
Generic Ozempic Will Upend the Global Weight-Loss Drug Market
